vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and CF BANKSHARES INC. (CFBK). Click either name above to swap in a different company.
CF BANKSHARES INC. is the larger business by last-quarter revenue ($15.7M vs $10.7M, roughly 1.5× Arbutus Biopharma Corp). CF BANKSHARES INC. runs the higher net margin — 40.0% vs 23.5%, a 16.6% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 12.6%). Over the past eight quarters, CF BANKSHARES INC.'s revenue compounded faster (13.7% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
CF Bankshares Inc. is a U.S.-based regional bank holding company operating through its community bank subsidiary. It offers a full suite of personal and commercial banking solutions including deposit products, various loan options, wealth management services and digital banking tools, primarily serving individual consumers and small-to-medium business clients across the U.S. Midwest region.
ABUS vs CFBK — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $15.7M |
| Net Profit | $2.5M | $5.7M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | 43.4% |
| Net Margin | 23.5% | 40.0% |
| Revenue YoY | 522.2% | 12.6% |
| Net Profit YoY | 112.7% | 29.9% |
| EPS (diluted) | $0.01 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $15.7M | ||
| Q3 25 | — | $15.5M | ||
| Q2 25 | $10.7M | $15.6M | ||
| Q1 25 | — | $14.1M | ||
| Q4 24 | — | $14.0M | ||
| Q3 24 | — | $13.1M | ||
| Q2 24 | — | $12.6M | ||
| Q1 24 | — | $12.2M |
| Q4 25 | — | $5.7M | ||
| Q3 25 | — | $2.3M | ||
| Q2 25 | $2.5M | $5.0M | ||
| Q1 25 | — | $4.4M | ||
| Q4 24 | — | $4.4M | ||
| Q3 24 | — | $4.2M | ||
| Q2 24 | — | $1.7M | ||
| Q1 24 | — | $3.1M |
| Q4 25 | — | 43.4% | ||
| Q3 25 | — | 17.5% | ||
| Q2 25 | 13.9% | 41.1% | ||
| Q1 25 | — | 39.5% | ||
| Q4 24 | — | 36.9% | ||
| Q3 24 | — | 40.4% | ||
| Q2 24 | — | 15.4% | ||
| Q1 24 | — | 30.9% |
| Q4 25 | — | 40.0% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | 23.5% | 32.3% | ||
| Q1 25 | — | 31.4% | ||
| Q4 24 | — | 35.2% | ||
| Q3 24 | — | 32.2% | ||
| Q2 24 | — | 13.5% | ||
| Q1 24 | — | 25.2% |
| Q4 25 | — | $0.88 | ||
| Q3 25 | — | $0.36 | ||
| Q2 25 | $0.01 | $0.77 | ||
| Q1 25 | — | $0.68 | ||
| Q4 24 | — | $0.68 | ||
| Q3 24 | — | $0.65 | ||
| Q2 24 | — | $0.26 | ||
| Q1 24 | — | $0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $259.0M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $83.0M | $184.4M |
| Total Assets | $103.3M | $2.1B |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $259.0M | ||
| Q3 25 | — | $272.4M | ||
| Q2 25 | $37.4M | $275.7M | ||
| Q1 25 | — | $241.0M | ||
| Q4 24 | — | $235.3M | ||
| Q3 24 | — | $233.5M | ||
| Q2 24 | — | $241.8M | ||
| Q1 24 | — | $236.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $184.4M | ||
| Q3 25 | — | $179.3M | ||
| Q2 25 | $83.0M | $177.0M | ||
| Q1 25 | — | $172.7M | ||
| Q4 24 | — | $168.4M | ||
| Q3 24 | — | $164.0M | ||
| Q2 24 | — | $159.6M | ||
| Q1 24 | — | $158.0M |
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | $103.3M | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $18.7M |
| Free Cash FlowOCF − Capex | — | $18.2M |
| FCF MarginFCF / Revenue | — | 115.6% |
| Capex IntensityCapex / Revenue | 0.0% | 3.1% |
| Cash ConversionOCF / Net Profit | -6.24× | 3.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | $33.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $18.7M | ||
| Q3 25 | — | $5.5M | ||
| Q2 25 | $-15.7M | $8.0M | ||
| Q1 25 | — | $2.2M | ||
| Q4 24 | — | $14.2M | ||
| Q3 24 | — | $-1.3M | ||
| Q2 24 | — | $4.0M | ||
| Q1 24 | — | $-1.2M |
| Q4 25 | — | $18.2M | ||
| Q3 25 | — | $5.2M | ||
| Q2 25 | — | $7.8M | ||
| Q1 25 | — | $2.2M | ||
| Q4 24 | — | $13.9M | ||
| Q3 24 | — | $-1.3M | ||
| Q2 24 | — | $4.0M | ||
| Q1 24 | — | $-1.2M |
| Q4 25 | — | 115.6% | ||
| Q3 25 | — | 33.6% | ||
| Q2 25 | — | 50.3% | ||
| Q1 25 | — | 15.2% | ||
| Q4 24 | — | 99.6% | ||
| Q3 24 | — | -9.9% | ||
| Q2 24 | — | 31.6% | ||
| Q1 24 | — | -9.5% |
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | 3.26× | ||
| Q3 25 | — | 2.34× | ||
| Q2 25 | -6.24× | 1.58× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | — | 3.21× | ||
| Q3 24 | — | -0.30× | ||
| Q2 24 | — | 2.35× | ||
| Q1 24 | — | -0.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
